Ovoca Bio PLC Holding(s) in Company (5916A)
January 23 2024 - 2:00AM
UK Regulatory
TIDMOVB
RNS Number : 5916A
Ovoca Bio PLC
23 January 2024
Ovoca Bio plc
("Ovoca" or the "Company")
Holding(s) in Company
Dublin, Ireland, January 23, 2024 - Ovoca Bio, a
biopharmaceutical company with a focus on women's health, received
notification from Mr. Leonid Skoptsov on 16 January 2024 that, as
of 17 October 2023, he holds an interest in 10,002,078 ordinary
shares of nominal value EUR0.125 each, which represents 12.26%* of
the Company's issued share capital (excluding treasury shares) .
The Company also received notification from Mr. Alexandr Mogutov on
16 January 2024 that, as of 17 October 2023, he no longer has a
notifiable interest in the Company's issued share capital
(excluding treasury shares).
*This percentage shareholding is based on a share in issue
figure of 81,563,806 ordinary shares of nominal value EUR0.125
each. The Company also holds 6,895,000 ordinary shares in treasury,
which do not carry voting rights.
End
For further information:
Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
info@ovocabio.com
Davy (Nominated Adviser, Euronext Growth Listing Sponsor and
Broker)
Ivan Murphy / Daragh O'Reilly
Tel: +353 1 679 6363
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a
focus on women's health. The Company is currently developing
Orenetide (BP-101), a novel synthetic peptide administered through
a nasal spray as a novel treatment for women with hypoactive sexual
desire disorder (HSDD), a condition characterized by a distressing
lack or loss of sexual desire affecting an estimated 4 million
premenopausal women in the US alone.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
HOLFIFSRLRIVFIS
(END) Dow Jones Newswires
January 23, 2024 02:00 ET (07:00 GMT)
Ovoca Bio (LSE:OVB)
Historical Stock Chart
From Oct 2024 to Nov 2024
Ovoca Bio (LSE:OVB)
Historical Stock Chart
From Nov 2023 to Nov 2024